Core Insights - Ariel Global Fund achieved a +23.30% return for the year 2025, outperforming both the MSCI ACWI and MSCI ACWI Value indices, although it lagged in the fourth quarter with a +2.88% return compared to +3.29% and +3.66% for the indices respectively [1] - The positive performance was supported by moderating inflation, easing financial conditions, and resilient corporate earnings, particularly driven by U.S. mega-cap technology stocks and a strong rebound in China [1] - Management remains optimistic about international equities, citing improving corporate fundamentals and attractive valuations, while emphasizing the importance of active stock selection in a market with increasing dispersion [1] Company Insights - Fresenius Medical Care AG (NYSE:FMS) is highlighted as a key stock in the Ariel Global Fund's portfolio, specializing in dialysis products and services for chronic kidney failure patients [2] - The stock of Fresenius Medical Care AG experienced a one-month return of -5.16%, with shares trading between $20.95 and $30.46 over the past 52 weeks, closing at approximately $22.21 on March 30, 2026, with a market capitalization of about $12.80 billion [2] - Despite mixed quarterly results, Fresenius Medical Care AG showed organic growth across all segments, although earnings were affected by restructuring costs; the company is viewed as attractively positioned from a risk/reward perspective due to improving profitability and strong cash generation [3]

Company Overview - Fresenius Medical Care AG & Co. KGaA is a leading provider of products and services for individuals undergoing dialysis due to chronic kidney failure, serving over 299,000 patients globally [11] - The company operates through two main segments: Care Delivery and Care Enablement, which contribute to its leadership in renal care [11] Investment Ratings - Fresenius is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A, indicating a solid overall performance [11] - The company has a Value Style Score of A, supported by attractive valuation metrics such as a forward P/E ratio of 8.81, making it appealing to value investors [12] Earnings Estimates - In the last 60 days, three analysts have revised their earnings estimates upwards for fiscal 2026, with the Zacks Consensus Estimate increasing by $0.02 to $2.49 per share [12] - Fresenius has demonstrated an average earnings surprise of +9.7%, indicating a positive trend in earnings performance [12]

Core Insights - DaVita Inc. (DVA) is experiencing growth due to its effective business model, with a strong performance in Q4 2025 and international expansion contributing to its positive outlook. However, there are ongoing concerns regarding its reliance on commercial payers for revenue generation [1][7]. Company Overview - DaVita has a market capitalization of $10.34 billion and projects a growth rate of 20.2% over the next five years. The company has exceeded earnings expectations in three of the last four quarters, with an average surprise of 1.2% [2]. Business Model - DaVita employs a patient-centric model that integrates a comprehensive kidney care platform, enhancing patient choice and care coordination. The company is involved in value-based arrangements and participates in CMMI's Comprehensive Kidney Care Contracting model, focusing on managing late-stage CKD and ESKD patients [3][4]. International Expansion - DaVita is expanding its presence in international markets, particularly in Brazil, China, Colombia, Germany, India, Malaysia, the Netherlands, Poland, Portugal, and Saudi Arabia through strategic alliances and acquisitions. The company aims to enhance patient care efficiency through these initiatives [5][8]. Q4 2025 Performance - DaVita reported better-than-expected results for Q4 2025, with revenue growth and margin expansion. The company has been actively acquiring and opening dialysis centers both in the U.S. and internationally, which is expected to positively impact its financial performance [10]. Strategic Partnerships - The company announced a strategic clinical partnership with Elara Caring to create a focused offering for end-stage kidney disease, aimed at reducing hospitalizations and improving patient experiences [11]. Revenue Dependence - DaVita's revenue is heavily reliant on commercial payers, which accounted for 26% of dialysis patient service revenues in 2025, despite representing only 11% of total U.S. dialysis patients. This dependence poses risks as shifts in payer mix could impact profitability [12][13]. Earnings Estimates - DaVita is experiencing a positive trend in earnings estimates for 2026, with the Zacks Consensus Estimate for earnings per share increasing to $14.16. The first-quarter 2026 revenue estimate is projected at $3.3 billion, reflecting a 2.4% increase from the previous year [14].

Core Thesis - DaVita Inc. is viewed positively by analysts, with shares trading at $154.79 and trailing and forward P/E ratios of 16.01 and 11.36 respectively [1] Financial Performance - DaVita generated $12.9 billion in revenue for 2025, with a modest organic growth of 0.6% and an adjusted operating profit of $2.094 billion [3] - The company maintains a strong financial quality with an adjusted operating margin of approximately 16.2% [4] Challenges - The primary challenge for DaVita is the decline in patient volume, with dialysis treatments decreasing by 1.1% during the year, which directly impacts revenue and profitability [4] - Revenue growth in the U.S. dialysis division was primarily driven by a 4.7% increase in revenue per treatment rather than an increase in patient volumes [5] Strategic Initiatives - Management is optimistic about clinical initiatives aimed at reducing patient mortality, which could potentially restore about 2% annual volume growth, although benefits may not be realized until around 2029 [5] - The Integrated Kidney Care (IKC) segment became profitable in 2025 with $22 million in operating profit, reflecting improved performance in value-based contracts rather than significant volume growth [6] - DaVita is pursuing a $200 million minority investment in Elara Caring to enhance patient outcomes and integrated care capabilities [6] Investment Outlook - The investment thesis is uncertain as success relies heavily on clinical outcomes rather than traditional operational improvements [7] - DaVita generates strong free cash flow of about $1 billion annually and engages in aggressive share repurchases, but projected EPS growth is largely attributed to buybacks rather than business expansion [7] - The company is characterized as financially strong but fundamentally defensive, with long-term performance contingent on the success of clinical initiatives to reverse declining patient volumes [7]

Core Insights - Fresenius Medical Care AG & Co. KGaA reported significant improvements in profitability for the 2025 financial year, with a focus on a new long-term strategy called "FME Reignite" aimed at 2030 [3][4] Financial Performance - Earnings per share increased by 44%, driven by strong earnings and an accelerated share buyback program [1] - Organic revenue growth for 2025 was 8%, with operating income growing by 31% and net income rising by 82% [2] - The operating income margin improved to 11.3%, aligning with the midterm target band of 10% to 14% set three years prior [2][7] - The company generated EUR 2.7 billion in operating cash flow and repurchased EUR 586 million in shares during 2025 [9] Strategic Initiatives - The FME25 program exceeded its original savings target, achieving EUR 804 million against an initial target of EUR 500 million, with a goal of EUR 1.2 billion in sustainable savings by 2027 [7] - The rollout of the 5008X hemodiafiltration (HDF) therapy in the U.S. is highlighted as the largest product launch in the company's history, with positive feedback from patients and staff [11][13] 2026 Outlook - Management anticipates 2026 to be a transition year with broadly flat revenue and an operating income margin of 10.5% to 12% as temporary benefits phase out [5][17] - Expected headwinds include EUR 250 million to EUR 350 million from business growth, EUR 200 million to EUR 300 million in inflationary impacts, and EUR 150 million to EUR 200 million in regulatory challenges [17] - The company plans to invest EUR 100 million to EUR 150 million in the HDF rollout and IT platform harmonization [16] Segment Performance - All three operating segments contributed positively to 2025 performance, with Care Delivery benefiting from FME25+ savings and positive rate effects [8] - Value-Based Care reported 34% revenue growth, while Care Enablement faced challenges from regulatory policies in China [8] Additional Insights - The company plans to propose a dividend of EUR 1.49 for 2025, reflecting a 3% increase from 2024 [10] - Management noted that U.S. treatment volumes were flat in 2025, with expectations for gradual recovery to 2%+ growth [19]

Financial Data and Key Metrics Changes - Fresenius Medical Care achieved a group margin of 11.3% for 2025, driven by all three operating segments, landing within the target margin band for the year [6][10] - Operating income growth reached 27%, marking the top end of the financial outlook for the year [7] - The company reported a significant increase in earnings growth of 53% in Q4, resulting in a margin of 13.9%, a 430 basis points increase year-over-year [13][19] Business Line Data and Key Metrics Changes - Care Delivery in the U.S. experienced flat same-market treatment growth, while international markets delivered 1.7% growth [13][14] - Value-Based Care achieved a break-even operating income for 2025, a notable improvement from a loss of EUR 28 million in 2024 [22] - Care Enablement revenue decreased by 3%, primarily due to regulatory pressures in China, but continued to see positive pricing contributions [23] Market Data and Key Metrics Changes - The U.S. market faced pressures from elevated medical benefit costs and lower volumes, impacting overall performance [7][14] - In China, regulatory policies and volume-based procurement negatively impacted revenue and earnings development [17][23] - The company expects a headwind from the phasing out of TDAPA regulations in 2026, which will affect revenue recognition [30][33] Company Strategy and Development Direction - Fresenius Medical Care launched its new 2030 strategy, FME Reignite, aimed at accelerating growth and improving profitability [5] - The company is focusing on the rollout of the 5008X CAREsystem, which is expected to enhance patient outcomes and operational efficiencies [28][39] - The FME25+ transformation program has delivered EUR 804 million in sustainable savings, exceeding targets and positioning the company for future growth [10][26] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by regulatory headwinds and elevated costs but remains committed to maintaining profitability while investing in future growth [30][39] - The outlook for 2026 anticipates broadly flat revenue growth, reflecting changes in Value-Based Care's risk contracting [30][33] - Management expressed confidence in achieving industry-leading growth and margins, with a target of 3%-7% compound annual growth rate through 2028 [38][39] Other Important Information - The company initiated a EUR 1 billion share buyback program, reflecting a strengthened financial profile and commitment to returning excess cash to shareholders [6][12] - A proposed dividend of EUR 1.49 for 2025 represents a 3% increase from 2024, aligning with the target payout ratio of 30%-40% [12] Q&A Session Summary Question: Key drivers of EBIT growth acceleration and impact of same-market treatment growth - Management indicated that 2026 is a year of investment, with flat growth expected due to regulatory impacts, but operational improvements are anticipated to drive future growth [46][48] Question: Impact of China tender modifications and outlook for 2026 - Management confirmed a EUR 50 million EBIT impact from China in 2025, expecting a lower impact in 2026 as they adapt to regulatory changes [49][50] Question: Clarification on phosphate binder contributions and expectations for 2026 - Management confirmed a EUR 220 million contribution in 2025, with expectations of a reduction in 2026 due to regulatory changes [53][56] Question: Thoughts on ACA subsidy headwinds moving to 2027 and 2028 - Management quantified ACA headwinds at around EUR 50 million and indicated ongoing assessments for future impacts [55][56] Question: Impact of higher insurance requirements on patient volume - Management acknowledged the importance of monitoring patient mix and enrollment trends, emphasizing a cautious approach to volume growth expectations [62][66]

Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [7][8] - Operating income margin improved to 11.3%, aligning with the midterm target band of 10%-14% [8][10] - Earnings per share increased by 44%, reflecting both earnings strength and the impact of the accelerated share buyback program [8][13] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [11] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [17] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and increased member months [9][17] - Care enablement revenue grew by 2% at constant currency, supported by volume growth and positive pricing [17][18] Market Data and Key Metrics Changes - Flat same-market treatment growth was observed in the U.S., with expectations for a 2%+ recovery due to quality initiatives and the introduction of the 5008X machine [8][9] - The company anticipates continued stagnant growth in U.S. treatment volumes for 2026, with a return to growth expected once mortality levels normalize [34][37] Company Strategy and Development Direction - The company introduced the FME Reignite strategy, focusing on operational excellence, growth and innovation, and cultural enhancement [4][5] - The 5008X machine launch in the U.S. is a significant strategic initiative aimed at improving patient outcomes and operational efficiency [14][15] - The company aims for a compound annual growth rate of 3%-7% in operating income through 2028, driven by the execution of the FME Reignite strategy [21][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and regulatory headwinds as significant challenges for 2026 [26][29] - The company is investing EUR 100 million to EUR 150 million in the rollout of the 5008X machine and IT platform harmonization [29][31] - Management expressed confidence in returning to a 2%+ growth in same-market treatment once mortality levels normalize [34][37] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [12] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [13] Q&A Session Questions and Answers Question: What is the biggest drag on the business currently? - Management indicated that ongoing inflationary pressures and costs related to the launch of the new dialysis device in the U.S. are significant factors [26][27] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - The estimated investment for the rollout is between EUR 100 million and EUR 150 million, with about half allocated to HDF [31][32] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat growth for 2026 but expressed confidence in returning to a 2%+ growth once mortality levels normalize [34][37] Question: What is your perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [39][40] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - The company is investing in its manufacturing plants in Schweinfurt and Sindelfingen, which are core producers of dialysis products [42][43]

Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [8][9] - Operating income margin improved to 11.3%, within the midterm target band of 10%-14% [9][12] - Earnings per share grew by 44%, reflecting earnings strength and the impact of the accelerated share buyback program [9][15] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [12][14] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [19] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and strong member months growth [10][19] - Care enablement revenue grew by 2% at constant currency, supported by volume growth and positive pricing developments [20] Market Data and Key Metrics Changes - Flat same-market treatment growth in the U.S. was observed, with expectations for a 2%+ recovery due to quality initiatives and the introduction of the 5008X machine [9][10] - The company anticipates continued stagnant growth in U.S. treatment volumes for 2026, with a gradual increase expected as mortality levels normalize [36][39] Company Strategy and Development Direction - The company introduced FME Reignite, a new 2030 strategy focusing on operational excellence, growth, and culture [4][5] - The FME25 transformation program exceeded its sustainable savings target, achieving EUR 804 million by year-end 2025 [6][13] - The company is strategically positioned for sustained value creation, targeting a compound annual growth rate of 3%-7% through 2028 [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and costs related to the launch of the new dialysis device in the U.S. as significant headwinds [27][31] - The outlook for 2026 is cautious, with expectations for broadly flat revenue growth and a focus on maintaining profitability while investing for future value creation [20][21] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [14] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [15] Q&A Session Questions and Answers Question: What is the biggest drag on the business currently? - Management indicated that ongoing inflationary pressures and costs related to the launch of the new dialysis device are significant factors [27][29] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - The estimated investment for the rollout of high-volume HDF and IT harmonization is between EUR 100 million and EUR 150 million, with about half allocated to HDF [33][34] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat volume growth for 2026 but expressed confidence in returning to a 2%+ growth once mortality levels normalize [36][39] Question: What is the perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [40][42] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - Investments are planned in manufacturing plants in Schweinfurt and Sindelfingen, which are core producers of dialysis products [43][44]

Financial Data and Key Metrics Changes - In 2025, organic revenue increased by 8%, reported operating income grew by 31%, and reported net income rose by 82% [7][8] - Operating income margin improved to 11.3%, within the midterm target band of 10%-14% [8][16] - Earnings per share grew by 44%, reflecting both earnings strength and the impact of the accelerated share buyback program [8][13] - Net leverage improved to 2.5x, down from 3.4x at the end of 2022 [11] Business Line Data and Key Metrics Changes - Care delivery segment revenue grew nearly 2% at constant currency, with organic revenue growth reaching almost 5% [17] - Value-based care segment saw organic revenue growth of 34%, driven by contract expansion and strong member months growth [9][17] - Care enablement revenue grew by 2% at constant currency, with operating income increasing by 33% at constant currency [18] Market Data and Key Metrics Changes - Flat same-market treatment growth in the U.S. was observed, with expectations of a 2%+ recovery due to quality initiatives [8][9] - The introduction of the 5008X machine in the U.S. is expected to improve treatment quality and operational efficiency [14][15] Company Strategy and Development Direction - The company introduced the FME Reignite strategy, focusing on operational excellence, growth and innovation, and cultural enhancement [4][5] - The FME25 transformation program exceeded its sustainable savings target, achieving EUR 804 million by year-end 2025 [6][12] - The company aims to maintain enhanced profitability while investing for future value creation, targeting a compound annual growth rate of 3%-7% through 2028 [20][22] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing inflationary pressures and regulatory headwinds as significant challenges for 2026 [25][29] - The company expects flat revenue growth in 2026, primarily due to changes in value-based care's risk contracting [19] - Management is confident in returning to a 2%+ growth in same-market treatment once mortality levels normalize [33][36] Other Important Information - The company generated EUR 2.7 billion in operating cash flow in 2025, demonstrating strong cash performance [12] - A dividend of EUR 1.49 is proposed for 2025, representing a 3% increase from 2024 [13] Q&A Session Summary Question: What is the biggest drag on the business: inflationary pressures or costs related to the new dialysis device launch? - Management indicated that both factors are significant, with an investment of EUR 100 million-EUR 150 million for the HDF launch and operational costs [25][29] Question: Can you estimate the cost for the large-scale 5008X launch in the U.S.? - Management estimated upfront costs for training and implementation at EUR 100 million-EUR 150 million, with half attributed to HDF [31][32] Question: When do you expect to see a turnaround in U.S. treatment volumes? - Management projected flat growth for 2026 but expressed confidence in returning to 2%+ growth once mortality levels normalize [33][34] Question: What is your perspective on the latest U.S. tariff changes? - Management noted that tariffs were immaterial in 2025 but expect some impact in 2026, monitoring developments closely [38][39] Question: In which locations in Germany is Fresenius Medical Care planning to invest? - Management highlighted investments in manufacturing plants in Schweinfurt and Sindelfingen, which are core to their production [40][41]

Core Insights - The S&P 500 index experienced a rise as investors reacted to mixed signals from the Federal Reserve regarding interest rates and inflation [1] - The Federal Reserve maintained interest rates but showed divided opinions on future actions, with some officials open to rate hikes if inflation persists, while others may consider cuts if inflation eases [1] - Recent economic data showed unexpected cooling in inflation, strong job growth, and a decrease in unemployment, contributing to ongoing market volatility [2] Value Investing - Value investing focuses on acquiring stocks priced below their intrinsic value, allowing investors to buy low and potentially profit later [3] - A key metric for value investors is earnings yield, which indicates the profit a company generates per dollar of its stock price, calculated as (Annual Earnings per Share/Market Price) x 100 [4] - Earnings yield can be compared to bond returns, such as the 10-year Treasury yield, to assess the attractiveness of stocks relative to fixed-income securities [5] Screening Criteria - A primary screening criterion for stock selection is an earnings yield greater than 10%, supplemented by estimated EPS growth for the next 12 months that meets or exceeds the S&P 500 average [6] - Additional criteria include an average daily trading volume of at least 100,000 shares and a current stock price of $5 or higher [7][8] Selected Stocks - Five stocks that meet the screening criteria include DaVita (DVA), Ford (F), Centerra Gold (CGAU), Southwest Airlines (LUV), and Patria Investments Limited (PAX), all showing strong earnings growth estimates [9] - DaVita is projected to have earnings growth of 31% and 19% for 2026 and 2027, respectively, with recent EPS estimates increasing by $1.59 and $2.38 [10] - Ford's earnings are expected to grow by 40% and 19% in 2026 and 2027, with EPS estimates rising by $0.05 each over the past month [11] - Centerra Gold anticipates earnings growth of 45% and 57% for 2026 and 2027, with EPS estimates increasing by $0.05 and $0.17 [12] - Southwest Airlines forecasts significant earnings growth of 362% and 17% for 2026 and 2027, with recent EPS estimates up by $0.17 and $0.08 [13] - Patria Investments expects earnings growth of 25% and 17% for 2026 and 2027, with EPS estimates rising by $0.04 and $0.07 [14]